Life sciences companies are at a crossroads: the decision to build in-house artificial intelligence (AI) capabilities or purchase existing solutions tailored for healthcare. This choice carries significant implications for their ability to leverage AI effectively and sustainably in drug development and commercialization.
The Dual Path: Build or Buy?
When opting to build, organizations face two primary avenues. The first involves customizing a general large language model to fit established workflows. While this approach seemingly offers a quicker start, many companies encounter obstacles due to data challenges and a lack of expertise in contextual engineering, often resulting in a failure to generate actionable insights.
The second option, building a proprietary solution from the ground up, presents even greater challenges. This path demands substantial investments of time and resources, making it a considerable undertaking. On the other hand, purchasing a fit-for-purpose solution requires meticulous evaluation to ensure the vendor possesses the specialized talent and infrastructure necessary for successful implementation.
Trust and Implementation: The Key Factors
A critical aspect of the build-or-buy decision is the level of trust in the vendor and the AI itself. Companies must rigorously assess whether the vendor’s capabilities align with their unique needs. This trust extends beyond the technology itself; it encompasses the overall strategy for AI implementation.
Unfortunately, many biopharma organizations launch AI initiatives in isolation, addressing one domain at a time, which can severely limit impact. A comprehensive AI strategy, conversely, fosters a unified framework for generating insights across the entire R&D-to-commercialization continuum, unlocking the full potential of AI.
Bridging the Valley of Death
The journey from discovery to commercial success is notoriously fraught with challenges. A staggering number of promising molecules fail to reach blockbuster status, often succumbing to the “valley of death” that encompasses clinical trials and market uptake. This reality raises an essential question: how can AI be harnessed to bridge this gap and expedite the delivery of life-changing therapies to patients?
By adopting a holistic AI strategy, companies open themselves to myriad opportunities. The advancements in AI over the past decade suggest that, had these technologies been available earlier, the landscape of drug development could look vastly different today.
Considerations for Building or Buying AI
The decision to build or buy AI capabilities hinges on three critical factors:
Talent Acquisition
Biopharma companies often lack the specialized expertise essential for sophisticated AI engineering. This expertise includes a deep understanding of healthcare data integration, domain knowledge, and familiarity with compliance and regulatory standards. Furthermore, the demand for bilingual experts—those proficient in both computational science and the nuances of biology or chemistry—adds another layer of complexity.
In the commercial sphere, professionals must navigate fragmented provider networks and complex payer landscapes while adhering to HIPAA regulations and marketing restrictions. The challenge of attracting and retaining such talent in a competitive environment cannot be overstated.
Speed to Market
For organizations that choose to build AI capabilities, the timeline from pilot to deployment can be extensive. Developing a healthcare-specific AI solution often takes two to four years before meaningful utility is achieved. Such delays can hinder the organization from capitalizing on AI’s most significant advantage: speed. Accelerating insight generation and decision-making is crucial in the fast-paced biopharma landscape.
Operational Focus
Building and maintaining AI technologies can divert resources and attention away from core drug development workflows. Leaders must weigh the initial development timeline against the opportunity cost of reallocating resources. Ensuring that the primary mission of delivering therapies to patients remains the focus is paramount.
The Impact of the Build vs. Buy Decision
The choice between building in-house capabilities or purchasing external solutions profoundly influences how quickly and reliably organizations can convert data into actionable insights. Developing AI internally may provide flexibility, but it necessitates a mature data infrastructure and sustained investment. Without these foundations, companies risk slow development cycles and inconsistent model performance, ultimately impacting crucial decision-making processes.
Even minor inefficiencies can disrupt timelines, resource allocation, and responsiveness to market signals. In contrast, fit-for-purpose external solutions can facilitate faster adoption and value delivery but require careful consideration regarding integration and governance.
A Strategic Approach to AI
Ultimately, the broader objective is to deploy AI in a way that strengthens scientific progress and enhances commercial performance. Balancing speed, capability, and risk is essential to ensure that organizations do not overextend their internal capacities while striving to innovate and improve patient outcomes.
The rapid evolution of AI capabilities presents both challenges and opportunities. Just a year ago, the idea of AI as a collaborative partner in drug development was merely a vision. As technology continues to advance, companies must remain adaptable and open to new possibilities.
Conclusion: The Path Forward
In conclusion, biopharma organizations must carefully evaluate whether to build or buy AI capabilities, considering factors such as talent acquisition, speed to market, and operational focus. Partnering with specialized vendors can allow companies to concentrate on their core mission of developing breakthrough therapies while leveraging advanced AI analytics. The future of drug development may hinge on this strategic decision, ultimately shaping how effectively companies can meet the pressing needs of patients and the healthcare system.
- Key Takeaways:
- Building in-house AI capabilities requires specialized talent and significant time investment.
- Purchasing fit-for-purpose solutions can accelerate AI integration but demands careful vendor evaluation.
- A comprehensive AI strategy can unlock insights across the entire R&D-to-commercialization continuum.
- Balancing speed, capability, and risk is critical for sustainable AI deployment.
- The rapid evolution of AI technologies necessitates adaptability in biopharma strategies.
Read more → www.pharmexec.com